Astellas Pharma (ALPMY) News Today $10.07 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementNovember 20 at 1:00 PM | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) & ADC Therapeutics (NYSE:ADCT) Critical ReviewNovember 20 at 2:53 AM | americanbankingnews.comAstellas Faces FDA Setback on IZERVAY ApplicationNovember 18 at 11:32 PM | markets.businessinsider.comABIVAX Société Anonyme (NASDAQ:ABVX) versus Astellas Pharma (OTCMKTS:ALPMY) Financial ContrastNovember 14, 2024 | americanbankingnews.comAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30, 2024 | markets.businessinsider.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 16.2% from the September 30th total of 38,800 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is presently 0.2 days.October 29, 2024 | marketbeat.comAstellas Pharma Withdraws EU Application for Key DrugOctober 28, 2024 | markets.businessinsider.comBernstein Releases a Buy Rating on Astellas Pharma (ALPMF)October 23, 2024 | markets.businessinsider.comAstellas Pharma’s VYLOY Gains FDA Approval for Cancer TreatmentOctober 21, 2024 | markets.businessinsider.comAstellas Pharma's Cancer Drug Vyloy Gets FDA ApprovalOctober 19, 2024 | marketwatch.comAstellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ CancerOctober 19, 2024 | markets.businessinsider.comAstellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ CancerOctober 18, 2024 | prnewswire.comFDA approves Astellas' gastric cancer therapyOctober 18, 2024 | reuters.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, an increase of 269.5% from the September 15th total of 10,500 shares. Based on an average trading volume of 139,900 shares, the short-interest ratio is currently 0.3 days.October 10, 2024 | marketbeat.comAstellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on MenopauseOctober 10, 2024 | prnewswire.comAstellas Receives Option To License AVB-101 - Quick FactsOctober 9, 2024 | markets.businessinsider.comAstellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other IndicationsOctober 8, 2024 | prnewswire.comSinglera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual MeetingOctober 1, 2024 | businesswire.comPoseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B AdvancementSeptember 30, 2024 | seekingalpha.comHere are the Medicare Part D drugs expected to face 2025 price negotiationsSeptember 29, 2024 | seekingalpha.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Decrease in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,500 shares, a drop of 75.4% from the August 31st total of 42,600 shares. Based on an average daily volume of 201,200 shares, the days-to-cover ratio is presently 0.1 days.September 25, 2024 | marketbeat.comAstellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerSeptember 20, 2024 | prnewswire.comAstellas Announces FDA Listing Of DIGITIVA For Heart Failure ManagementSeptember 18, 2024 | markets.businessinsider.comAstellas Announces FDA Listing of DIGITIVA™ for the Management of Heart FailureSeptember 18, 2024 | prnewswire.comAstellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024September 11, 2024 | prnewswire.comAstellas opens lab, offices in Cambridge CrossingSeptember 6, 2024 | bizjournals.comAstellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough TherapiesSeptember 5, 2024 | prnewswire.comAstellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause SocietySeptember 4, 2024 | prnewswire.comSanten Pharmaceutical Co., Ltd. (SZD.F)August 30, 2024 | sg.finance.yahoo.comAstellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial CancerAugust 27, 2024 | markets.businessinsider.comEuropean Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial CancerAugust 27, 2024 | prnewswire.comAstellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine TherapyAugust 27, 2024 | prnewswire.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 11.9% in JulyAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large decrease in short interest in July. As of July 31st, there was short interest totalling 298,700 shares, a decrease of 11.9% from the July 15th total of 338,900 shares. Based on an average daily trading volume, of 530,700 shares, the days-to-cover ratio is currently 0.6 days.August 17, 2024 | marketbeat.comAstellas' zolbetuximab gains UK approval for gastric cancerAugust 16, 2024 | msn.comUK regulator approves Astellas' gastric cancer drugAugust 14, 2024 | reuters.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Above 50 Day Moving Average of $10.38Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50-Day Moving Average of $10.38August 14, 2024 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Above 50-Day Moving Average of $10.18Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50 Day Moving Average of $10.18August 6, 2024 | marketbeat.comSmall-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor DataAugust 5, 2024 | finance.yahoo.comAstellas: Zolbetuximab Combo Gets Positive CHMP Opinion In Advanced Gastric &Gastroesophageal CancerJuly 28, 2024 | markets.businessinsider.comAstellas Wins CHMP Backing for Treatments Aimed at Bladder, Gastric CancerJuly 27, 2024 | marketwatch.comAstellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction CancerJuly 26, 2024 | prnewswire.comAstellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerJuly 26, 2024 | prnewswire.comAstellas, Osaka University To Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell TherapyJuly 22, 2024 | markets.businessinsider.comAstellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell TherapyJuly 22, 2024 | prnewswire.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 10.5%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 227,800 shares, a drop of 10.5% from the June 15th total of 254,500 shares. Based on an average daily volume of 518,500 shares, the short-interest ratio is currently 0.4 days.July 15, 2024 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 83.5% in JuneAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 254,500 shares, an increase of 83.5% from the May 31st total of 138,700 shares. Based on an average daily volume of 839,200 shares, the short-interest ratio is presently 0.3 days.June 28, 2024 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Expands By 87.2%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 138,700 shares, an increase of 87.2% from the May 15th total of 74,100 shares. Based on an average daily trading volume, of 647,900 shares, the short-interest ratio is presently 0.2 days.June 13, 2024 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 11.7% in MayAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 74,100 shares, a decrease of 11.7% from the April 30th total of 83,900 shares. Based on an average daily volume of 564,700 shares, the short-interest ratio is presently 0.1 days.June 1, 2024 | marketbeat.comU.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATEMay 30, 2024 | prnewswire.comAstellas Pharma partners with YASKAWA for innovative cell therapyMay 21, 2024 | msn.com Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! ALPMY Media Mentions By Week ALPMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼-0.180.45▲Average Medical News Sentiment ALPMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼32▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Today TAK News Today UCBJF News Today ALNY News Today MKKGY News Today TEVA News Today BGNE News Today MKGAF News Today UTHR News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
